{
    "eid": "2-s2.0-84928230979",
    "title": "Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand",
    "cover-date": "2015-04-24",
    "subject-areas": [
        {
            "$": "Pharmacology (medical)",
            "@code": "2736"
        },
        {
            "$": "Virology",
            "@code": "2406"
        },
        {
            "$": "Molecular Medicine",
            "@code": "1313"
        }
    ],
    "keywords": [],
    "authors": [
        "Weerawat Manosuthi"
    ],
    "citedby-count": 82,
    "ref-count": 69,
    "ref-list": [
        "Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR\u00ae) for the treatment of advanced HIV-infected patients: A 24-week study",
        null,
        null,
        null,
        "Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010",
        "Recommendations for a public health approach",
        "Antiretroviral treatment of adult HIV infection: 2014 Recommendations of the International Antiviral Society-USA panel",
        "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents",
        "Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy",
        "Effect of early versus deferred antiretroviral therapy for HIV on survival",
        "When to initiate combined antiretroviral therapy to reduce mortality and aids-defining illness in HIV-infected persons in developed countries",
        "Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters",
        "Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART Study",
        "Long-term CD4 cell count recovery among Thai naive HIV-infected patients initiating HAART at low CD4 cell count",
        "Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies",
        "Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: Results from the phase 3 HPTN 052 randomised controlled trial",
        "Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL",
        "Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine",
        "Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: Results From the TIME study",
        "Survival rate and risk factors of mortality among HIV/tuberculosis- coinfected patients with and without antiretroviral therapy",
        "Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: Clinical experiences from Thailand",
        "Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand",
        "Timing of initiation of antiretroviral drugs during tuberculosis therapy",
        "Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis",
        "Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis",
        "Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): A prospective, international, randomised, placebo-controlled trial",
        "Timing of antiretroviral therapy for HIV-1 infection and tuberculosis",
        "Comparison of clinical features and survival between cryptococcosis in human immunodeficiency virus (HIV)-positive and HIV-negative patients",
        "Mortality rate of early versus deferred initiation of antiretroviral therapy in HIV-1-infected patients with cryptococcal meningitis",
        "Survival time of HIV-infected patients with cryptococcal meningitis",
        "Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: A multicenter randomized strategy trial",
        "Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa",
        "Optimal timing for antiretroviral therapy initiation in patients with HIV infection and concurrent cryptococcal meningitis",
        "Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy.",
        "Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France",
        "The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy",
        "Life-threatening immune reconstitution inflammatory syndrome after Pneumocystis pneumonia: A cautionary case series",
        "Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection.",
        "2014 update of the drug resistance mutations in HIV-1",
        "Class-sparing regimens for initial treatment of HIV-1 infection",
        "Risk factors for mortality in symptomatic hyperlactatemia among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting",
        "Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study",
        "Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV",
        "Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: A randomized trial",
        "Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials",
        "Efavirenz-Based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts",
        "Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials",
        "Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial",
        "Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial",
        "Outcomes for Efavirenz versus Nevirapine-Containing Regimens for Treatment of HIV-1 Infection: A Systematic Review and Meta-Analysis",
        "Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV",
        "Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127",
        "Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals",
        "Safety of efavirenz in the first trimester of pregnancy: An updated systematic review and meta-analysis",
        "Management of individuals requiring antiretroviral therapy and TB treatment",
        "Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections",
        "An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with hiv infection",
        "Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin",
        "Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin",
        "Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 Weeks results",
        null,
        "Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin",
        "Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis",
        "Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: A randomised non-inferiority trial",
        "Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): A multicentre, phase 2, non-comparative, open-label, randomised trial",
        "Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: Week 96 results from the ANRS 139 TRIO trial",
        "Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): A randomised, open-label, non-inferiority study",
        "7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013)",
        "A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: The HIV STAR study"
    ],
    "affiliation": [
        {
            "affiliation-city": "Nontaburi",
            "affilname": "Thailand Ministry of Public Health",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nontaburi",
            "affilname": "National Health Security Office",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Khon Kaen",
            "affilname": "Khon Kaen University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "The HIV Netherlands Australia Thailand Research Collaboration",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Faculty of Medicine Ramathibodi Hospital, Mahidol University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Faculty of Medicine Siriraj Hospital, Mahidol University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Srinakharinwirot University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Thai AIDS Society",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Thailand Research Fund"
    ]
}